DBSA

Axsome Therapeutics Joins the National Alliance on Mental Illness and Others Advocating for the Importance of Mental Health on Mental Illness Awareness Week

Retrieved on: 
Monday, October 2, 2023
Clifford Whittingham Beers, Mental Illness Awareness Week, National Alliance, American Foundation for Suicide Prevention, DBSA, Central nervous system, Depression, Anxiety, Prevalence, OCD, Education, DSM-IV codes, Suicide, Overalls, AFSP, Quality of life, Hope, Research, CNS, Mental, Organization, 988 Suicide & Crisis Lifeline, National Alliance on Mental Illness, Medicine, Central nervous system disease, Risk, Mental disorder, Pleasure, NAMI, ADAA, Therapy, Counselor, Mental health, MHA, PTSD, Nursing

In support of MIAW, Axsome is sponsoring NAMI’s “Inspiring Hope Through Research” event in Washington D.C. on Oct. 11.

Key Points: 
  • In support of MIAW, Axsome is sponsoring NAMI’s “Inspiring Hope Through Research” event in Washington D.C. on Oct. 11.
  • This year’s awardee, Sabine Wilhelm, Ph.D., has been advancing the use of technology, such as smartphone-based treatments, to help people with mental health problems.
  • DBSA is a leading national peer-focused mental health organization, whose mission is to provide hope, help, support, and education for individuals who live with mood disorders.
  • NAMI is the nation’s largest grassroots mental health organization dedicated to building better lives for the millions of Americans affected by mental illness.

Fabre-Kramer Pharmaceuticals Announces FDA Approval of EXXUA™, the First and Only Oral Selective 5HT1a Receptor Agonist for the Treatment of Major Depressive Disorder in Adults

Retrieved on: 
Thursday, September 28, 2023
Blood pressure, DBSA, Depression, University, DSM-IV codes, Pharmacy, COVID-19, Quality of life, University of California, Gepirone, CNS, Weight gain, University of Virginia School of Medicine, Fabre-Kramer Pharmaceuticals, Dizziness, MDD, Severe cutaneous adverse reactions, MD, Patient, NCE, Effectiveness, Grammatical mood, Nausea, Heart rate, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Neurology, Virginia School for Girls, Food, Chair, Pharmaceutical industry, Dietary supplement, Psychiatry

HOUSTON, Sept. 28, 2023 /PRNewswire/ -- Fabre-Kramer Pharmaceuticals Inc. (Fabre-Kramer), a biopharmaceutical company committed to developing novel therapies to address unmet needs in psychiatry and neurology, is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved Exxua™ (gepirone hydrochloride extended-release tablets) for the treatment of major depressive disorder (MDD) in adults. Exxua represents a new class of antidepressant; the first and only approved antidepressant with a novel mechanism of action that selectively targets the serotonin 1A receptor, a key regulator of mood and emotion. Exxua has been shown to effectively relieve depressive symptoms, and its approved labeling does not contain Warnings or Adverse Reactions regarding causing sexual dysfunction or weight gain vs. placebo. Exxua is expected to be available in pharmacies in early 2024.

Key Points: 
  • EXXUA is the first new chemical entity (NCE) utilizing this single mechanism approved for the treatment of major depressive disorder.
  • Exxua has been shown to effectively relieve depressive symptoms, and its approved labeling does not contain Warnings or Adverse Reactions regarding causing sexual dysfunction or weight gain vs. placebo.
  • Studied in over 5,000 patients, EXXUA's unique mechanism of targeted single serotonin (5HT) 1a receptor agonism relieves depressive symptoms with an acceptable side effect profile.
  • Over 20 million American adults experienced major depressive disorder each year prior to the COVID-19 pandemic.

Axsome Therapeutics Joins Mental Health America and the State of New York to Raise Awareness of Mental Health During May is Mental Health Month

Retrieved on: 
Monday, May 1, 2023
Clifford Whittingham Beers, National Alliance, Substance Abuse, 988 Suicide & Crisis Lifeline, DBSA, Central nervous system, Depression, Lifeline, Anxiety, National Alliance on Mental Illness, Prevalence, OCD, Education, DSM-IV codes, Suicide, SAMHSA, Overalls, Quality of life, Substance Abuse and Mental Health Services Administration, Hope, Research, Disorder, CNS, Organization, One World Trade Center, Risk, Mental disorder, Pleasure, ADAA, NAMI, Anxiety and Depression Association of America, Ageing, Health, Therapy, Counselor, Mental health, MHA, Environment, PTSD, Nursing

NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, is joining Mental Health America (MHA) and the State of New York to raise awareness of mental health during May is Mental Health Month.

Key Points: 
  • NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, is joining Mental Health America (MHA) and the State of New York to raise awareness of mental health during May is Mental Health Month.
  • In observance of the beginning of May is Mental Health Month, Axsome’s new corporate headquarters, One World Trade Center in New York City, will be lit in green, the color for mental health awareness, on May 1, 2023.
  • Axsome is supporting this year’s MHA ‘look around, look within’ campaign in observance of May is Mental Health Month.
  • Axsome is proud to stand in solidarity with MHA and other national organizations that provide mental health resources to those in need.

Alkermes Announces Recipients of 2022 Alkermes Inspiration Grants® Program

Retrieved on: 
Thursday, October 27, 2022
People, Ovarian cancer, YPR, Community, DBSA, Young People, Organization, Language, Research, Learning management system, Program, Stigma, Neuroscience, Child, Native, Alkermes (company), Native Americans, Adult, Cancer, Depression, Parent, Mortality, Survivor, Patient, City, Genetics, Population, Caregiver, Education, Lists of diseases, Social inequality, Friends, National Association for Children of Alcoholics, Mental health, Vaccines for Children Program, AUD, Diagnosis, Substance use disorder, Schizophrenia, Ownership, Color, List of largest cities, Opioid, Bipolar I disorder, Bipolar disorder, Tobacco, Organic, Cancer Research Institute, Nasdaq, Awareness, ACeS, Addiction, Woman, ALKS, SUD, FWC, Opioid use disorder, Nation, Pharmaceutical industry, Residential care, Risk management, Medicine, Alkermes

DUBLIN, Oct. 27, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the 2022 recipients of the Alkermes Inspiration Grants® program. Grants were awarded to nine nonprofit organizations working to address the needs of people living with alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and cancer. The selected programs also have a focus on addressing unmet needs in historically under-resourced or underrepresented communities with longstanding and widespread health disparities.

Key Points: 
  • 6th Installment of Competitive Grants Program Awards Funding to Nine Innovative Programs Focused on People Living with Addiction, Serious Mental Illness or Cancer
    DUBLIN, Oct. 27, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the 2022 recipients of the Alkermes Inspiration Grants program.
  • "This year's Alkermes Inspiration Grants recipients inspire us with their innovative approaches to providing critical support for people living with addiction, serious mental illness or cancer, as well as their caregivers and family members.
  • Since 2016, the Alkermes Inspiration Grants program has awarded more than $4.5 million in funding to innovative programs that support the needs of those impacted by serious diseases in our areas of focus.
  • For more information on the Alkermes Inspiration Grants program, please visit https://www.alkermes.com/responsibility .

Depression and Bipolar Support Alliance Lauds House Passage Of Restoring Hope for Mental Health Well-Being Act Of 2022

Retrieved on: 
Wednesday, June 29, 2022
Well, Topical steroid withdrawal, Depression and Bipolar Support Alliance (Greater Houston), D-NV, House, Senate, Attention, Legislation, Bipolar disorder, Lists of diseases, Workforce, COVID-19, Depression, DBSA, Representative, Software, Mental health, Language, Leadership, Online gambling

CHICAGO (June 28, 2022) The Depression and Bipolar Support Alliance (DBSA) today applauded passage of H.R.

Key Points: 
  • CHICAGO (June 28, 2022) The Depression and Bipolar Support Alliance (DBSA) today applauded passage of H.R.
  • 7666, also known as the Restoring Hope For Mental Health Well-Being Act of 2022.
  • The bill, passed with overwhelming bipartisan support by a vote of 402-20, contains funding for peer support services including virtual peer support group meetings.
  • The pandemic lockdowns demonstrated that access to mental health support and treatment is needed and can be delivered through virtual modalities.

Axsome Therapeutics Announces Results of the SUPPORT Survey of Patients with Major Depressive Disorder Presented at the American Society of Clinical Psychopharmacology Association (ASCP) 2022 Annual Meeting

Retrieved on: 
Monday, June 6, 2022
People, Company, Migraine, WHO, Hope, Food and Drug Administration, Washington University in St. Louis, Food, Central nervous system, Depression, MDD, Disability, GEMINI, National, Work, ASCEND, Bipolar disorder, MD, NDA, Patient, CNS, World, World Health Organization, University, Lists of diseases, Suicide, ASCP, Psychiatry, University of Toronto, Physician, Grammatical mood, Prevalence, Solriamfetol, Education, Impact, DBSA, Research, Society, Annual general meeting, Therapy, FDA, GLOBE, Pleasure, Fools and Worthless Liars, NASDAQ, Clinical trial, Guilt, Medical device, Pharmaceutical industry, COVID-19, Pharmacology

NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the results of the SUPPORT (Studying the Impact of Patient Treatment Experiences on Patient Hope for Future Major Depressive Disorder Pharmacotherapies) survey of 385 patients with depression, demonstrating persistence of high levels of depressive symptoms despite treatment, substantial interference with work and daily life, low levels of patient hope, and high levels of patient dissatisfaction with current treatments.

Key Points: 
  • The SUPPORT survey assessed treatment experiences and expectations in patients taking antidepressants for major depressive disorder (MDD).
  • The SUPPORT results were presented on June 1, 2022 at the American Society of Clinical Psychopharmacology (ASCP) 2022 Annual Meeting, held in Scottsdale, Arizona and virtually.
  • We are pleased to partner with Axsome to increase support for and empower those experiencing depression.
  • Despite 85% of survey participants being currently on an antidepressant, 68% were still experiencing moderate, severe, or very severe depressive symptoms.

DEPRESSION AND BIPOLAR SUPPORT ALLIANCE TO HONOR THREE OUTSTANDING ACHIEVERS IN MENTAL HEALTH RESEARCH AT 2022 KLERMAN AWARDS CEREMONY MAY 22

Retrieved on: 
Thursday, May 12, 2022
Drinking, Knowledge, Anxiety, Global Health, Gerald, Lists of diseases, Alcohol, National, Collaborative RESearch Team to study psychosocial issues in Bipolar Disorder (CREST.BD), Suicidal ideation, Patient, National Institute, Mental health, Collaboration, Gerald Klerman, American Society for Pharmacology and Experimental Therapeutics, Quality of life, Therapy, Clinical trial, DBSA, McGovern Medical School, National academy, Mortality, Bipolar disorder, University, Depression, Autism, Research, Psychosis, Psychotherapy, Bipolar, Genetics, TRD, National Institute of Mental Health, Disability, CDT, Harvard Medical School, Panic, NIMH, Coronavirus Scientific Advisory Board (Turkey), Depression and Bipolar Support Alliance (Greater Houston), Diagnosis, Schizophrenia, SAB, GLOBE, Pharmaceutical industry, Medicine

Chicago, IL, May 12, 2022 (GLOBE NEWSWIRE) -- CHICAGO (May 12, 2022) The Depression and Bipolar Support Alliance (DBSA), and its Scientific Advisory Board (SAB) will honor three clinicians for their contributions to mental health research at the 2022 Klerman Awards ceremony.

Key Points: 
  • Chicago, IL, May 12, 2022 (GLOBE NEWSWIRE) -- CHICAGO (May 12, 2022) The Depression and Bipolar Support Alliance (DBSA), and its Scientific Advisory Board (SAB) will honor three clinicians for their contributions to mental health research at the 2022 Klerman Awards ceremony.
  • Gerald L. Klerman was an educator, researcher, clinician, author, and administrator who specialized in depression, schizophrenia, panic, and other anxiety disorders.
  • Their relentless pursuit of progress in mental health research ensures a brighter future of improved diagnosis and treatments for those living with depression and bipolar disorder.
  • This year, the Klerman Awards ceremony celebrates these outstanding achievers in mental health research:
    Dr. Zarate is Chief, Experimental Therapeutics and Pathophysiology Branch, at the National Institute of Mental Health (NIMH).

DBSA PEER SPECIALIST INSTRUCTOR AND MILITARY VETERAN PROVIDES TESTIMONY IN SUPPORT OF PENDING LEGISLATION FOR THE VIRTUAL PEER SUPPORT ACT

Retrieved on: 
Tuesday, April 5, 2022
Well, Hearing, Family, Depression and Bipolar Support Alliance, Congress, DBSA, Mental health, Energy, Legislation, Caregiver, Friends, Mood disorder, Social support, CEO, Health, Lists of diseases, Hope, Smith, COVID-19, Student, Education, Depression, Animal, Tutoring

(CHICAGO) LeVail Smith, Peer Specialist and instructor for the Depression and Bipolar Support Alliance (DBSA ), spoke Tuesday as a panelist at the Energy and Commerce Health Subcommittee hearing in support of pending legislation H.R.

Key Points: 
  • (CHICAGO) LeVail Smith, Peer Specialist and instructor for the Depression and Bipolar Support Alliance (DBSA ), spoke Tuesday as a panelist at the Energy and Commerce Health Subcommittee hearing in support of pending legislation H.R.
  • As an instructor for the DBSA Peer Support Specialist course and a mentor for other peers participating in the DBSA peer apprentice program, Smith shared his experiences as an individual in recovery and wellness living with a mental health issue and substance use condition.
  • 2929, the Virtual Peer Support Act that, if it becomes law, will provide funding to expand access to virtual peer support services, including virtual support group meetings, and provide training to individuals who want to become state-certified peer support specialists.
  • We have seen the demand for DBSA virtual support groups jump by more than 137% since the start of the pandemic, said Michael Pollock, CEO of DBSA.

New National Survey of People Living with Bipolar I Disorder Provides Insights Into Disease-Related Challenges and the Treatment Journey

Retrieved on: 
Thursday, January 6, 2022
BD, Caregiver, Family, Lists of diseases, Knowledge, Grammatical mood, ALKS, The Harris Poll, Harris, Alkermes (company), Research, Education, Depression, Bipolar I disorder, Adult, Social support, Intention, Neurodegeneration, Cancer, Uncertainty, Life, Motivation, Medical Affairs Bureau, Sexual desire, Ageing, Annual report, Neurological disorder, Risk, DBSA, Private Securities Litigation Reform Act, Disease, Awareness, Hope, SEC, Mania, Disorder, Decision-making, Public relations, Schizophrenia, Somnolence, Diagnosis, Weight gain, Population, Nasdaq, National Comorbidity Survey, Prevalence, Anxiety, Mood disorder, Multimedia, U.S. Securities and Exchange Commission, Bipolar disorder, Friends, Pharmaceutical industry, Risk management, Health insurance, Alkermes

Despite the challenges that some people living with BD-I face in their treatment journey, many respondents (75%) reported feeling well-managed on their then-current BD-I medication regimen.

Key Points: 
  • Despite the challenges that some people living with BD-I face in their treatment journey, many respondents (75%) reported feeling well-managed on their then-current BD-I medication regimen.
  • The results of this survey do not necessarily represent the experiences of the broader population of people living with BD-I.
  • Bipolar disorder is a brain disorder that is marked by extreme changes in a person's mood, energy and ability to function.
  • Lifetime and 12-Month Prevalence of Bipolar Spectrum Disorder in the National Comorbidity Survey Replication.

New National Survey of People Living with Bipolar I Disorder Provides Insights Into Disease-Related Challenges and the Treatment Journey

Retrieved on: 
Thursday, January 6, 2022
BD, Caregiver, Family, Lists of diseases, Knowledge, Grammatical mood, ALKS, The Harris Poll, Harris, Alkermes (company), Research, Education, Depression, Bipolar I disorder, Adult, Social support, Intention, Neurodegeneration, Cancer, Uncertainty, Life, Motivation, Medical Affairs Bureau, Sexual desire, Ageing, Annual report, Neurological disorder, Risk, DBSA, Private Securities Litigation Reform Act, Disease, Awareness, Hope, SEC, Mania, Disorder, Decision-making, Public relations, Schizophrenia, Somnolence, Diagnosis, Weight gain, Population, Nasdaq, National Comorbidity Survey, Prevalence, Anxiety, Mood disorder, U.S. Securities and Exchange Commission, Bipolar disorder, Friends, Pharmaceutical industry, Risk management, Health insurance, Alkermes

DUBLIN, Jan. 6, 2022 /PRNewswire/ -- Results from a newly released survey provide insights from adults living with bipolar I disorder (BD-I)* in the United States (U.S.) on the burden of living with this serious mental health condition and their experiences with treatment. This research was conducted in support of Alkermes' commitment to understanding the unique needs of people living with BD-I and supporting increased disease awareness and education. 

Key Points: 
  • Despite the challenges that some people living with BD-I face in their treatment journey, many respondents (75%) reported feeling well-managed on their then-current BD-I medication regimen.
  • The results of this survey do not necessarily represent the experiences of the broader population of people living with BD-I.
  • Bipolar disorder is a brain disorder that is marked by extreme changes in a person's mood, energy and ability to function.
  • Lifetime and 12-Month Prevalence of Bipolar Spectrum Disorder in the National Comorbidity Survey Replication.